Clinical Trial Update: A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1b open-label study evaluating safety and pharmacokinetics of subcutaneous blinatumomab in relapsed/refractory indolent non-Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Amgen | Conditions: Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2024-02-02